Advertisement
SGN-CD33A demonstrates encouraging antileukemic activity
Showcasing the latest science from Cleveland Clinic
Researchers hope findings will inspire multicenter trial
Results from Phase III CATCH trial add data to what was already a consensus-driven treatment option: low-molecular weight heparin.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
Advertisement